Fact sheet: Candriam Eq L Btchnlg

Fund information

Fund name
Candriam Equities L Biotechnology N USD
Fund company manager
Candriam Investors Group
Fund type
SIB
Fund manager
Rudi VAN DEN EYNDE
since 06/04/2000
Fund objective
The subfund invests in biotechnology companies and in related activities (e.g. molecular diagnostics & scientific equipment). It has a worldwide scope but given the innovative history of the US biotechnology sector, most of the assets are invested in the US. The fund is not managed against a specific benchmark.
Benchmark
No Specified Index
Investment style
Growth
Investment method
Shares

Quick stats

1 Year return

20.57 %

1 Year rank in sector

2/29

Sector

FO Equity - Pharma Health & Biotech

Yield
-
Fund size

£ 790.9 m

FE Risk score

233

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    93.41%
  • Others
    6.59%
  • Biotechnology/Medical
    99.65%
  • Others
    0.35%
  • International Equities
    98.7%
  • Others
    1.3%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund10.1 %14.64 %20.57 %26.96 %139.13 %
Sector4.51 %4.02 %9.81 %21.13 %99.13 %
Rank within sector1 / 302 / 302 / 297 / 272 / 23
Quartile th1 st1 st1 st2 nd1 st

Calendar performance

YTD-20172016201520142013
Fund30.8 %-19.92 %7.62 %34.91 %63.77 %
Sector15.98 %-9.92 %7.24 %28.08 %41.03 %
Rank within sector3 / 2926 / 2914 / 279 / 242 / 23
Quartile th1 st4 th3 rd2 nd1 st

Risk statistics

Alpha-1.26
Beta1.54
Sharpe0.19
Volatility25.79
Tracking error13.53
Information ratio0.07
R-Squared0.84

Price movement

52 week high435.52
52 week low297.24
Current bid price0
Current offer price0
Current mid price428.25

Holdings by region

  • 93.41% USA
  • 6.59% Others

Holdings by sector

  • 99.65% Biotechnology/Medical
  • 0.35% Others

Holdings by asset type

  • 98.7% International Equities
  • 1.3% Others

Individual holdings

  • 7.17% GILEAD SCIENCES INC
  • 6.69% BIOGEN INC
  • 6.5% CELGENE CORP
  • 6.36% REGENERON PHARMACEUTICALS INC
  • 5.21% INCYTE CORP
  • 4.75% VERTEX PHARMACEUTICAL
  • 4.6% AMGEN INC
  • 3.32% ALEXION PHARMACEUTICALS INC
  • 2.72% TESARO INC
  • 2.57% NEUROCRINE BIOSCIENCES INC